Terada Koji, Kondo Kenta, Ishigaki Hirohito, Nagashima Ayaka, Satooka Hiroki, Nagano Seiji, Masuda Kyoko, Kawamura Teruhisa, Hirata Takako, Ogasawara Kazumasa, Itoh Yasushi, Kawamoto Hiroshi, Agata Yasutoshi
Department of Biochemistry and Molecular Biology, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga 520-2192, Japan.
Department of Pathology, Shiga University of Medical Science, Otsu 520-2192, Japan.
Mol Ther Oncolytics. 2021 Dec 6;24:77-86. doi: 10.1016/j.omto.2021.12.003. eCollection 2022 Mar 17.
To develop effective adoptive cell transfer therapy using T cell receptor (TCR)-engineered T cells, it is critical to isolate tumor-reactive TCRs that have potent anti-tumor activity. In humans, tumor-infiltrating lymphocytes (TILs) have been reported to contain CD8PD-1 T cells that express tumor-reactive TCRs. Characterization of tumor reactivity of TILs from non-human primate tumors could improve anti-tumor activity of TCR-engineered T cells in preclinical research. In this study, we sought to isolate TCR genes from CD8PD-1 T cells among TILs in a cynomolgus macaque model of tumor transplantation in which the tumors were infiltrated with CD8 T cells and were eventually rejected. We analyzed the repertoire of TCRα and β pairs obtained from single CD8PD-1 T cells in TILs and circulating lymphocytes and identified multiple TCR pairs with high frequency, suggesting that T cells expressing these recurrent TCRs were clonally expanded in response to tumor cells. We further showed that the recurrent TCRs exhibited cytotoxic activity to tumor cells and potent anti-tumor activity in mice transplanted with tumor cells. These results imply that this tumor transplantation macaque model recapitulates key features of human TILs and can serve as a platform toward preclinical studies of non-human primate tumor models.
为了利用工程化T细胞受体(TCR)的T细胞开发有效的过继性细胞转移疗法,分离具有强大抗肿瘤活性的肿瘤反应性TCR至关重要。在人类中,据报道肿瘤浸润淋巴细胞(TIL)含有表达肿瘤反应性TCR的CD8+PD-1+ T细胞。对来自非人类灵长类动物肿瘤的TIL的肿瘤反应性进行表征,可在临床前研究中提高工程化TCR T细胞的抗肿瘤活性。在本研究中,我们试图从食蟹猕猴肿瘤移植模型的TIL中的CD8+PD-1+ T细胞中分离TCR基因,在该模型中肿瘤被CD8 T细胞浸润并最终被排斥。我们分析了从TIL和循环淋巴细胞中的单个CD8+PD-1+ T细胞获得的TCRα和β对库,并鉴定了多个高频TCR对,这表明表达这些重复出现的TCR的T细胞因肿瘤细胞而发生克隆性扩增。我们进一步表明,这些重复出现的TCR对肿瘤细胞表现出细胞毒性活性,并在移植了肿瘤细胞的小鼠中具有强大的抗肿瘤活性。这些结果表明,这种肿瘤移植猕猴模型概括了人类TIL的关键特征,并可作为非人类灵长类动物肿瘤模型临床前研究的平台。